← Back to Search

Monoclonal Antibodies

TST005 for Cancer

Phase 1
Waitlist Available
Research Sponsored by Suzhou Transcenta Therapeutics Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 90 days following last dose
Awards & highlights

Study Summary

This trial is testing a new cancer treatment that targets two proteins involved in cancer growth. The study will help researchers learn if the treatment is safe and effective.

Eligible Conditions
  • Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 90 days following last dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 90 days following last dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Part A - Determine the maximum tolerated dose (MTD) or recommended Phase 2 dose(s) (RP2D)
Part B - Patient safety as characterized by frequency and severity of adverse events
Secondary outcome measures
Immunogenicity of TST005
Part A - Area under Plasma concentration vs. time curve (AUC) for TST005
Part A - Peak Plasma concentration (Cmax) for TST005
+8 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Part B - Dose ExpansionExperimental Treatment1 Intervention
Participants with any kind of advanced or HPV metastatic solid tumors dosed Q3W with the Part A Q3W recommended dose of TST005
Group II: Part A - Dose EscalationExperimental Treatment1 Intervention
Dosed every 3 weeks IV with TST005, starting dose is 1 mg/kg, and 5 dose levels will be tested.

Find a Location

Who is running the clinical trial?

Suzhou Transcenta Therapeutics Co., Ltd.Lead Sponsor
7 Previous Clinical Trials
1,605 Total Patients Enrolled
Transcenta TherapeuticsLead Sponsor
Charlie Qi, MDStudy DirectorSuzhou Transcenta Therapeutics Co., Ltd.

Media Library

TST005 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04958434 — Phase 1
Cancer Research Study Groups: Part A - Dose Escalation, Part B - Dose Expansion
Cancer Clinical Trial 2023: TST005 Highlights & Side Effects. Trial Name: NCT04958434 — Phase 1
TST005 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04958434 — Phase 1
~5 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top